 DUBLIN and SOUTH SAN FRANCISCO, Calif., Aug. 23, 2021 PRNewswire -- Theravance Biopharma, Inc. Theravance Biopharma or the Company NASDAQ: TBPH, a diversified biopharmaceutical company primarily focused on the discovery, development, and commercialization of organ-selective medicines, today announced top-line results from its Phase 2b dose-finding induction study of izencitinib, an orally administered, gut-selective pan-Janus kinase JAK inhibitor in development for the treatment of ulcerative colitis. 